

Technical Bulletin

Nebulizer Characterization for the Methacholine Challenge Test

The 2017 ERS technical standard on direct challenge testing recommends using PD₂₀ to interpret methacholine challenge test results.¹ Methapharm has characterized an additional nebulizer with Provocholine® to provide this information.

$$\text{Delivered Dose} = \begin{array}{c} \text{inhaled mass} \\ \text{(mg/min)} \end{array} \times \begin{array}{c} \text{respirable fraction} \\ \text{(\% of particles } < 5 \mu\text{m)} \end{array} \times \begin{array}{c} \text{inhalation time} \\ \text{(in minutes)} \end{array}$$

Table 1. Nebulizer Performance with Provocholine® 16 mg/mL Concentration

| Adult | | | | | |
|---|----------------------------------|-----------------|-----------------------|--------------------------|-------------------------------|
| Nebulizer | Powered by (lb/in ²) | Flow Rate (LPM) | Inhaled Mass (mg/min) | Respirable Fraction* (%) | Estimated Deposition (mg/min) |
| English Wright ¹ | 50 | 8 | 0.19 | 100 | 0.19 |
| Hudson RCI® MicroMist® Small Volume Nebulizer | 50 | 5 | 0.675 | 68.8 | 0.464 |

* The respirable fraction is the percentage of particles <5 µm¹

Key Considerations When Selecting a Nebulizer:

- Nebulizers have evolved over the years and in some cases have a much higher output. The duration of tidal breathing may need to be decreased from two minutes in order to deliver the appropriate dose. In the Hudson RCI® MicroMist® Small Volume Nebulizer calculation below only one-minute of nebulization is required.

Using the nebulizer performance characteristics from Table 1, the Provocholine® dose delivered to an adult using a 16 mg/mL concentration can be calculated as follows:

English Wright (2-minute tidal breathing)
(0.19) x (1) x (2) = 0.38 mg (380 µg)

Hudson RCI® MicroMist® Small Volume Nebulizer (1-minute tidal breathing)
(0.675) x (0.688) x (1) = 0.464 mg (464 µg)

Technical Bulletin

The ERS technical standard recommends a starting dose between 1 and 3 µg and to not exceed a maximum dose of 800 µg.

Table 2. Dose delivered to an adult according to the ATS quadrupling concentrations protocol

| Concentration | 0.0625 mg/mL | 0.25 mg/mL | 1 mg/mL | 4 mg/mL | 16 mg/mL |
|--|--------------|------------|----------|-----------|----------|
| English Wright¹ (2-minute tidal breathing) | 1.48 µg | 5.94 µg | 23.75 µg | 95 µg | 380 µg |
| Hudson RCI[®] MicroMist[®] Small Volume Nebulizer (1-minute tidal breathing) | 1.81 µg | 7.26 µg | 29.03 µg | 116.10 µg | 464.4 µg |

Nebulizer Characterization Protocol

All studies were performed as per United States Pharmacopeia (USP) 1601 Products for Nebulization Characterization Tests. The Hudson RCI[®] MicroMist[®] Small Volume Nebulizer was powered by dry compressed air, regulated to 50 lb/in² (psi) and a flow controller set to a flow rate of 5.0 LPM. The solution used was Provocholine[®] (methacholine chloride) at a concentration of 16 mg/mL. The particle size distribution was measured by Next Generation Impactor (NGI). A Copley Breath Simulator was set-up using the adult profile: 500 mL for tidal volume, 15 breaths (Cycles)/min, inhalation/exhalation ratio 1:1 and a sinusoidal waveform.

WARNING: SEVERE BRONCHOCONSTRICTION

Severe bronchoconstriction can result from Provocholine administration (including the lowest dose). The use of Provocholine is contraindicated in pediatric and adult patients with baseline FEV₁ < 60% predicted or adults with FEV₁ < 1.5 L. Because of the potential for severe bronchoconstriction, the use of Provocholine in patients with clinically apparent asthma or wheezing is not recommended [see Warnings and Precautions – Section 5.1 of the Prescribing Information].

Emergency equipment and medication should be immediately available to treat acute respiratory distress. If severe bronchoconstriction occurs, reverse immediately with a rapid-acting inhaled bronchodilator agent (β-agonist) [see Warnings and Precautions – Section 5.1 of the Prescribing Information].

If baseline spirometry is not performed or is measured inaccurately, the initial FEV₁ may be underestimated. In this situation, decreases in FEV₁ may not be detected after administration of escalating Provocholine doses, which may result in administration of unnecessary higher doses and an increased risk for excessive bronchoconstriction [see Warnings and Precautions – Section 5.1 of the Prescribing Information].

Please consult the package insert for full prescribing information available for download at www.provocholine.com or on request by calling Methapharm Medical Information at 1-866-701-4636. You are encouraged to report adverse reactions of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA(332)-1088. This information is provided as a professional courtesy, and it is intended to provide data available to us that may assist you in deriving your own conclusions and opinions. This information is not intended to advocate any indications, dosage, or other described in the package insert. For all other inquiries, please call 1-833-887-7686 for Customer Service.

Reference: 1. Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. *Eur Respir J* 2017;49:1601526

Provocholine[®] is a registered trademark of Methapharm Inc., 81 Sinclair Blvd, Brantford, ON, N3S 7X6, Canada. Hudson RCI[®] and MicroMist[®] are the trademarks or registered marks of Teleflex Incorporated.

Copyright © Methapharm Inc., 2021


Specialty Pharmaceuticals

PROVO-105-NEB-EN-10-25-21

For more information, please contact Methapharm at 1-833-887-7686